In a nutshell This study aimed to investigate the outcomes for patients with chronic lymphocytic leukemia (CLL), with genetic abnormalities (mutated IGHV) and without del(17p)/TP53 mutation, who were treated with the iFCG (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) regimen. This study concluded that this treatment regimen is...
Read More
In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...
Read More
In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment. This study concluded that TFR is safe and durable in these patients. Some background The...
Read More
In a nutshell This study aimed to compare outcomes for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) receiving chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) after achieving complete remission. This study concluded that chemotherapy led to better outcomes for these patients when...
Read More
In a nutshell This study aimed to investigate the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to tyrosine kinase inhibitor (TKI) treatment. This study concluded that...
Read More
In a nutshell This study aimed to investigate if consolidation chemotherapy before reduced-intensity conditioning (RIC) allogeneic hemopoietic stem cell transplant (alloHSCT) improved outcomes for patients with acute myeloid leukemia (AML). This study concluded that exposure to consolidation chemotherapy before RIC alloHSCT may help patients...
Read More
In a nutshell This study aimed to investigate the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) who were treated with venetoclax (Venclexta) and decitabine (Dacogen). This study concluded that a negative MRD status after 1, 2, and 4 months of therapy predicts better...
Read More
In a nutshell This study aimed to investigate if restricting calories and nutrients from diet and exercise could change chemotherapy effectiveness in patients with B-cell acute lymphoblastic leukemia (ALL). This study concluded that restricting calories/nutrients via diet and exercise changed chemotherapy effectiveness and...
Read More
In a nutshell This study aimed to review existing evidence regarding the outcome of tyrosine kinase inhibitor (TKI) maintenance therapy after allogeneic stem-cell transplantation (allo-SCT) in patients with FLT3-ITD mutated (genetic abnormality) acute myeloid leukemia (AML). This study concluded that TKI maintenance therapy after...
Read More
In a nutshell This study aimed to investigate the long-term outcomes for children with acute myeloid leukemia (AML) who were treated with low-dose chemotherapy (LDC). This study concluded that there is a high remission rate for these patients and that long-term survival is similar to patients who...
Read More
In a nutshell This study aimed to investigate if the combination of dasatinib and hyperfractionated cyclophosphamide (Cytoxan), vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (Decadron) – hyperCVAD – would be safe and effective for patients with chronic myeloid leukemia (CML) in...
Read More
In a nutshell This study aimed to compare the safety and effectiveness of intensive and less-intensive therapy for older adults with acute myeloid leukemia (AML). This study concluded that intensive therapy may lead to better outcomes for these patients when compared to less-intensive therapy. Some background Older patients with...
Read More
